EGFR H773_V774insH

CI-VAR-00001929Explore in graph →CIViC 1446

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma3
EGFR H773_V774insH	Erlotinib	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID5940 A 74 year old female former smoker with 8 pack years and EGFR H773_V774insH lung adenocarcinoma patient was given erlotinib as second line treatment, and had progressive disease as best response with … (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
EGFR H773_V774insH	Erlotinib	Predictive	D	Supports Resistance	—	accepted	EID4276 In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M … (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.